Get the Stockscreener App
24.30
5.74%
-1.48
Metsera Inc stock is traded at $24.30, with a volume of 111.39K.
It is down -5.74% in the last 24 hours and down -19.08% over the past month.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
See More
Previous Close:
$25.78
Open:
$25.73
24h Volume:
111.39K
Relative Volume:
0.48
Market Cap:
$2.72B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-9.73%
1M Performance:
-19.08%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$24.19
$26.03
1-Week Range:
$23.91
$27.29
52-Week Range:
$23.91
$32.81
Metsera Inc Stock (MTSR) Company Profile
Compare MTSR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
24.23 | 2.72B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.54 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
678.02 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.05 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.79 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.47 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-25 | Initiated | BofA Securities | Buy |
| Feb-25-25 | Initiated | Evercore ISI | Outperform |
| Feb-25-25 | Initiated | Guggenheim | Buy |
Metsera Inc Stock (MTSR) Latest News
Top 10 Insider Purchases Last Month - Insider Monkey
Metsera, Inc. awards full bonuses to executive officers By Investing.com - Investing.com Australia
Metsera, Inc. awards full bonuses to executive officers - Investing.com India
Metsera, Inc. Approves 2024 Executive Cash Bonuses - TipRanks
Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
Why Did MTSR Stock Surge 15% On The Worst Trading Day Of 2025? Here's What Has Happened Since Its Listing - NewsBreak
Why Did Metsera Stock Surge 15% On The Worst Trading Day Of 2025? Here's What Has Happened Since Its Listing - Benzinga
Metsera, Inc. (MTSR): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
10 Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
10 Best Weight Loss Drug Stocks to Buy According to Analysts - Insider Monkey
CenExel Supports Metsera, Inc. in Successful Phase II Trial of MET-097 for Obesity and Metabolic Diseases - ACCESS Newswire
Metsera to Present at TD Cowen's 45th Annual Health Care Conference - The Manila Times
Metsera to Present at TD Cowen’s 45th Annual Health Care Conference - The Bakersfield Californian
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation - Seeking Alpha
Metsera (NASDAQ:MTSR) Now Covered by Bank of America - Defense World
Metsera (NASDAQ:MTSR) Now Covered by Analysts at Evercore ISI - Defense World
Metsera started by Guggenheim at buy on obesity drug opportunity - MSN
Wall Street bullish on Metsera following January IPO on obesity drug pipeline - Investing.com Canada
Metsera started at buy at Guggenheim on obesity treatment potential - MSN
Why this newly public biotech could become a force in obesity treatments - MarketWatch
90% upside? This weight-loss drug play is worth a look - Invezz
This weight-loss drug stock could deliver a 90% return in 2025 - TradingView
Cantor Fitzgerald initiates Metsera with overweight rating - Investing.com India
Cantor Fitzgerald initiates Metsera with overweight rating By Investing.com - Investing.com Australia
Metsera, Inc.: Buy Rating Affirmed Due to Innovative Obesity Market Approach and Strong Growth Catalysts - TipRanks
Metsera initiated with an Outperform at Evercore ISI - TipRanks
BofA sets Metsera stock Buy rating, $38 price target By Investing.com - Investing.com South Africa
BofA sets Metsera stock Buy rating, $38 price target - Investing.com India
Metsera, Inc.: A Promising Buy in the Obesity Market with Potential for Significant Returns - TipRanks
Guggenheim sets Metsera stock Buy rating, $56 target By Investing.com - Investing.com South Africa
Guggenheim sets Metsera stock Buy rating, $56 target - Investing.com India
10 Stocks Insiders Spent The Most Money On Recently - Insider Monkey
Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently - Insider Monkey
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut - MSN
Aardvark Therapeutics Gets $94 Million IPO to Power Obesity Treatments - BioSpace
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares - The Manila Times
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to - EIN News
Metsera shares leap on strong IPO performance By Investing.com - Investing.com Nigeria
Metsera shares leap on strong IPO performance - MSN
Metsera IPO opens 42% higher - MSN
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s - MedCity News
Metsera, Maze land on NASDAQ as IPO queue grows - BioCentury
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs - MSN
Metsera sees stock rally 54% following $275M IPO - MSN
Metsera Inc Stock (MTSR) Financials Data
There is no financial data for Metsera Inc (MTSR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):